[{"id":"5895dd46-f4f2-46c6-9499-4596f2c29417","acronym":"","url":"https://clinicaltrials.gov/study/NCT06011772","created_at":"2023-08-25T15:08:32.780Z","updated_at":"2025-02-25T14:03:46.296Z","phase":"Phase 1","brief_title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06011772","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/04/2025","primary_completion_date":" 12/04/2025","study_txt":" Completion: 12/04/2026","study_completion_date":" 12/04/2026","last_update_posted":"2025-02-19"},{"id":"5ac6e248-8ceb-4558-800b-74838c401239","acronym":"","url":"https://clinicaltrials.gov/study/NCT02955290","created_at":"2021-01-18T14:31:09.469Z","updated_at":"2024-07-02T16:35:29.892Z","phase":"Phase 1/2","brief_title":"CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","source_id_and_acronym":"NCT02955290","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation • ROS1 mutation","tags":["PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 12/22/2016","start_date":" 12/22/2016","primary_txt":" Primary completion: 12/09/2027","primary_completion_date":" 12/09/2027","study_txt":" Completion: 12/09/2027","study_completion_date":" 12/09/2027","last_update_posted":"2023-11-08"},{"id":"1f128534-e6a9-4adc-991e-90de12ce52cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04298606","created_at":"2021-01-18T20:51:10.175Z","updated_at":"2024-07-02T16:35:41.401Z","phase":"Phase 1","brief_title":"A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence","source_id_and_acronym":"NCT04298606","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CimaVax EGF (EGF-PTI)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/22/2021","start_date":" 11/22/2021","primary_txt":" Primary completion: 11/22/2024","primary_completion_date":" 11/22/2024","study_txt":" Completion: 11/22/2024","study_completion_date":" 11/22/2024","last_update_posted":"2023-08-01"},{"id":"31455c2c-ff0c-44b3-849c-ae43fb5fde26","acronym":"EPICAL","url":"https://clinicaltrials.gov/study/NCT03623750","created_at":"2021-01-18T17:48:13.570Z","updated_at":"2024-07-02T16:36:07.996Z","phase":"Phase 1/2","brief_title":"E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C","source_id_and_acronym":"NCT03623750 - EPICAL","lead_sponsor":"Instituto Oncológico Dr Rosell","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CimaVax EGF (EGF-PTI) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 07/06/2018","start_date":" 07/06/2018","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2022-06-30"}]